SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-279097
Filing Date
2022-11-07
Accepted
2022-11-07 16:16:22
Documents
14
Period of Report
2022-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d411939d8k.htm   iXBRL 8-K 24899
2 EX-99.1 d411939dex991.htm EX-99.1 51868
6 GRAPHIC g411939g1107063713848.jpg GRAPHIC 2585
  Complete submission text file 0001193125-22-279097.txt   209194

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avir-20221107.xsd EX-101.SCH 2867
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20221107_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20221107_pre.xml EX-101.PRE 10820
8 EXTRACTED XBRL INSTANCE DOCUMENT d411939d8k_htm.xml XML 3229
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 221365662
SIC: 2834 Pharmaceutical Preparations